{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:28:33Z","timestamp":1791822513625,"version":"4.3.4"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T00:00:00Z","timestamp":1486598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T00:00:00Z","timestamp":1486598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/nrcardio.2017.12","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T06:11:08Z","timestamp":1486620668000},"page":"294-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Single or dual antiplatelet therapy after PCI"],"prefix":"10.1038","volume":"14","author":[{"given":"Yosuke","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pannipa","family":"Suwannasom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Sotomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Tummala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan","family":"Tenekecioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cavalcante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Onuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"BFnrcardio201712_CR1","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1161\/01.CIR.98.16.1597","volume":"98","author":"ME Bertrand","year":"1998","unstructured":"Bertrand, M. E.  et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 98, 1597\u20131603 (1998).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR2","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl, S. R.  et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288, 2411\u20132420 (2002).","journal-title":"JAMA"},{"key":"BFnrcardio201712_CR3","first-page":"e574","volume":"124","author":"GN Levine","year":"2011","unstructured":"Levine, G. N.  et al. 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124, e574\u2013e651 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR4","doi-asserted-by":"crossref","unstructured":"Task Force Members  et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 34, 2949\u20133003 (2013).","DOI":"10.1093\/eurheartj\/eht296"},{"key":"BFnrcardio201712_CR5","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Windecker, S.  et al. 2014 ESC\/EACTS guidelines on myocardial revascularization: the Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 35, 2541\u20132619 (2014).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201712_CR6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine, G. N.  et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 68, 1082\u20131115 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi, M.  et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 37, 267\u2013315 (2016).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201712_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0002-8703(82)90486-0","volume":"103","author":"A Gruentzig","year":"1982","unstructured":"Gruentzig, A. Results from coronary angioplasty and implications for the future. Am. Heart J. 103, 779\u2013783 (1982).","journal-title":"Am. Heart J."},{"key":"BFnrcardio201712_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1056\/NEJM197907123010201","volume":"301","author":"AR Gr\u00fcntzig","year":"1979","unstructured":"Gr\u00fcntzig, A. R., Senning, A. & Siegenthaler, W. E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 301, 61\u201368 (1979).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1161\/01.CIR.69.4.721","volume":"69","author":"MA Thornton","year":"1984","unstructured":"Thornton, M. A., Gruentzig, A. R., Hollman, J., King, S. B. III & Douglas, J. S. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation 69, 721\u2013727 (1984).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","volume":"334","author":"A Sch\u00f6mig","year":"1996","unstructured":"Sch\u00f6mig, A.  et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334, 1084\u20131089 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR12","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","volume":"339","author":"MB Leon","year":"1998","unstructured":"Leon, M. B.  et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med. 339, 1665\u20131671 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta, S. R.  et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527\u2013533 (2001).","journal-title":"Lancet"},{"key":"BFnrcardio201712_CR14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa012843","volume":"346","author":"MC Morice","year":"2002","unstructured":"Morice, M. C.  et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346, 1773\u20131780 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1056\/NEJMoa035071","volume":"349","author":"JW Moses","year":"2003","unstructured":"Moses, J. W.  et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349, 1315\u20131323 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa032441","volume":"350","author":"GW Stone","year":"2004","unstructured":"Stone, G. W.  et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350, 221\u2013231 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.108.842757","volume":"119","author":"S Cook","year":"2009","unstructured":"Cook, S. & Windecker, S. Early stent thrombosis: past, present, and future. Circulation 119, 657\u2013659 (2009).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","volume":"369","author":"J Daemen","year":"2007","unstructured":"Daemen, J.  et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369, 667\u2013678 (2007).","journal-title":"Lancet"},{"key":"BFnrcardio201712_CR19","first-page":"405","volume":"2","author":"PW Serruys","year":"2007","unstructured":"Serruys, P. W. FDA panel, 7 and 8 December 2006 \u2014the impact on our practice and research. EuroIntervention 2, 405\u2013407 (2007).","journal-title":"EuroIntervention"},{"key":"BFnrcardio201712_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","volume":"65","author":"M Gilard","year":"2015","unstructured":"Gilard, M.  et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J. Am. Coll. Cardiol. 65, 777\u2013786 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR21","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri, L.  et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Engl. J. Med. 371, 2155\u20132166 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR22","first-page":"2510","volume":"310","author":"F Feres","year":"2013","unstructured":"Feres, F.  et al. Three versus twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310, 2510\u20132522 (2013).","journal-title":"JAMA"},{"key":"BFnrcardio201712_CR23","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","volume":"36","author":"S Schulz-Schupke","year":"2015","unstructured":"Schulz-Schupke, S.  et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur. Heart J. 36, 1252\u20131263 (2015).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201712_CR24","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","volume":"125","author":"M Valgimigli","year":"2012","unstructured":"Valgimigli, M.  et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125, 2015\u20132026 (2012).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR25","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jacc.2015.05.053","volume":"66","author":"G Montalescot","year":"2015","unstructured":"Montalescot, G., Brieger, D., Dalby, A. J., Park, S. J. & Mehran, R. Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence. J. Am. Coll. Cardiol. 66, 832\u2013847 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","volume":"125","author":"HC Gwon","year":"2012","unstructured":"Gwon, H. C.  et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience\/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation 125, 505\u2013513 (2012).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR27","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","volume":"65","author":"G Giustino","year":"2015","unstructured":"Giustino, G.  et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 65, 1298\u20131310 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jama.2015.1671","volume":"313","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes, D. J.  et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA 313, 1113\u20131121 (2015).","journal-title":"JAMA"},{"key":"BFnrcardio201712_CR29","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jcin.2015.05.026","volume":"8","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes, D. J.  et al. Stent thrombosis in drug-eluting or bare-metal stents in patients receiving dual antiplatelet therapy. JACC Cardiovasc. Interv. 8, 1552\u20131562 (2015).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio201712_CR30","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","volume":"375","author":"KH Bonaa","year":"2016","unstructured":"Bonaa, K. H.  et al. Drug-eluting or bare-metal stents for coronary artery disease. N. Engl. J. Med. 375, 1242\u20131252 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR31","unstructured":"PR Newswire. Abbott's XIENCE PRIME\u2122 and XIENCE V\u00ae drug eluting stents receive indication in Europe for minimum three-month duration of dual anti-platelet therapy. PRNewswire http:\/\/www.prnewswire.com\/news-releases\/abbotts-xience-prime-and-xience-v-drug-eluting-stents-receive-indication-in-europe-for-minimum-three-month-duration-of-dual-anti-platelet-therapy-151509525.html (2012)."},{"key":"BFnrcardio201712_CR32","unstructured":"Medtronic. Medtronic approved to update resolute integrity stent's 'CE' mark labeling on dual antiplatelet therapy. Medtronic http:\/\/newsroom.medtronic.com\/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=1802668&highlight (2013)."},{"key":"BFnrcardio201712_CR33","unstructured":"Angioplasty.org. Medtronic stent gets CE Mark label update for one month of DAPT. PTCA http:\/\/www.ptca.org\/news\/2013\/0304_MEDTRONIC_RESOLUTE.html (2013)."},{"key":"BFnrcardio201712_CR34","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","volume":"373","author":"SG Ellis","year":"2015","unstructured":"Ellis, S. G.  et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N. Engl. J. Med. 373, 1905\u20131915 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR35","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.4244\/EIJY16M09_01","volume":"12","author":"Y Onuma","year":"2016","unstructured":"Onuma, Y.  et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. EuroIntervention 12, 1090\u20131101 (2016).","journal-title":"EuroIntervention"},{"key":"BFnrcardio201712_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/eurheartj\/ehv500","volume":"37","author":"M Sabate","year":"2016","unstructured":"Sabate, M.  et al. Everolimus-eluting bioresorbable stent versus durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur. Heart J. 37, 229\u2013240 (2016).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201712_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jacc.2014.12.017","volume":"65","author":"S Puricel","year":"2015","unstructured":"Puricel, S.  et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J. Am. Coll. Cardiol. 65, 791\u2013801 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR38","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jacc.2015.09.054","volume":"66","author":"R Gao","year":"2015","unstructured":"Gao, R.  et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J. Am. Coll. Cardiol. 66, 2298\u20132309 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR39","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","volume":"388","author":"PW Serruys","year":"2016","unstructured":"Serruys, P. W.  et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet 388, 2479\u20132491 (2016).","journal-title":"Lancet"},{"key":"BFnrcardio201712_CR40","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(15)01039-9","volume":"387","author":"GW Stone","year":"2016","unstructured":"Stone, G. W.  et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet 387, 1277\u20131289 (2016).","journal-title":"Lancet"},{"key":"BFnrcardio201712_CR41","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1161\/CIRCULATIONAHA.109.921528","volume":"122","author":"Y Onuma","year":"2010","unstructured":"Onuma, Y.  et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 122, 2288\u20132300 (2010).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR42","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","volume":"373","author":"P Urban","year":"2015","unstructured":"Urban, P.  et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N. Engl. J. Med. 373, 2038\u20132047 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","volume":"9","author":"S Ariotti","year":"2016","unstructured":"Ariotti, S.  et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: a pre-specified analysis from the ZEUS trial. JACC Cardiovasc. Interv. 9, 426\u2013436 (2016).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio201712_CR44","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","volume":"68","author":"JA Bittl","year":"2016","unstructured":"Bittl, J. A., Baber, U., Bradley, S. M. & Wijeysundera, D. N. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 68, 1116\u20131139 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR45","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","volume":"68","author":"G Giustino","year":"2016","unstructured":"Giustino, G.  et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J. Am. Coll. Cardiol. 68, 1851\u20131864 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR46","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","volume":"49","author":"DL Bhatt","year":"2007","unstructured":"Bhatt, D. L.  et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. 49, 1982\u20131988 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR47","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca, M. P.  et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791\u20131800 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR48","first-page":"390","volume":"37","author":"JA Udell","year":"2016","unstructured":"Udell, J. A.  et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur. Heart J. 37, 390\u2013399 (2016).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201712_CR49","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.2016.3775","volume":"315","author":"RW Yeh","year":"2016","unstructured":"Yeh, R. W.  et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315, 1735\u20131749 (2016).","journal-title":"JAMA"},{"key":"BFnrcardio201712_CR50","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.jacc.2005.01.030","volume":"45","author":"PA Gurbel","year":"2005","unstructured":"Gurbel, P. A.  et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol. 45, 1392\u20131396 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR51","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","volume":"373","author":"JP Collet","year":"2009","unstructured":"Collet, J. P.  et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309\u2013317 (2009).","journal-title":"Lancet"},{"key":"BFnrcardio201712_CR52","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega, J. L.  et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354\u2013362 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR53","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","volume":"51","author":"L Bonello","year":"2008","unstructured":"Bonello, L.  et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404\u20131411 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR54","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","volume":"51","author":"D Trenk","year":"2008","unstructured":"Trenk, D.  et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol. 51, 1925\u20131934 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","volume":"12","author":"F Franchi","year":"2015","unstructured":"Franchi, F. & Angiolillo, D. J. Novel antiplatelet agents in acute coronary syndrome. Nat. Rev. Cardiol. 12, 30\u201347 (2015).","journal-title":"Nat. Rev. Cardiol."},{"key":"BFnrcardio201712_CR56","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000028398","volume":"61","author":"PJ Wedlund","year":"2000","unstructured":"Wedlund, P. J. The CYP2C19 enzyme polymorphism. Pharmacology 61, 174\u2013183 (2000).","journal-title":"Pharmacology"},{"key":"BFnrcardio201712_CR57","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3949\/ccjm.78a.10145","volume":"78","author":"JP Kitzmiller","year":"2011","unstructured":"Kitzmiller, J. P., Groen, D. K., Phelps, M. A. & Sadee, W. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve. Clin. J. Med. 78, 243\u2013257 (2011).","journal-title":"Cleve. Clin. J. Med."},{"key":"BFnrcardio201712_CR58","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone, G. W.  et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382, 614\u2013623 (2013).","journal-title":"Lancet"},{"key":"BFnrcardio201712_CR59","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","volume":"119","author":"JL Mega","year":"2009","unstructured":"Mega, J. L.  et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119, 2553\u20132560 (2009).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR60","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"D Trenk","year":"2012","unstructured":"Trenk, D.  et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J. Am. Coll. Cardiol. 59, 2159\u20132164 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR61","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.111.029165","volume":"124","author":"MJ Price","year":"2011","unstructured":"Price, M. J.  et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124, 1132\u20131137 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR62","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jama.2011.290","volume":"305","author":"MJ Price","year":"2011","unstructured":"Price, M. J.  et al. Standard- versus high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097\u20131105 (2011).","journal-title":"JAMA"},{"key":"BFnrcardio201712_CR63","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","volume":"367","author":"JP Collet","year":"2012","unstructured":"Collet, J. P.  et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367, 2100\u20132109 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR64","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1161\/CIRCULATIONAHA.113.007524","volume":"129","author":"G Montalescot","year":"2014","unstructured":"Montalescot, G.  et al. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: a landmark analysis of the ARCTIC study. Circulation 129, 2136\u20132143 (2014).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR65","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","volume":"388","author":"G Cayla","year":"2016","unstructured":"Cayla, G.  et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 388, 2015\u20132022 (2016).","journal-title":"Lancet"},{"key":"BFnrcardio201712_CR66","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel, P. A.  et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation 120, 2577\u20132585 (2009).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR67","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","volume":"27","author":"S Husted","year":"2006","unstructured":"Husted, S.  et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 27, 1038\u20131047 (2006).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201712_CR68","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D.  et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001\u20132015 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR69","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin, L.  et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045\u20131057 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR70","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","volume":"375","author":"CP Cannon","year":"2010","unstructured":"Cannon, C. P.  et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375, 283\u2013293 (2010).","journal-title":"Lancet"},{"key":"BFnrcardio201712_CR71","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt, D. L.  et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl. J. Med. 368, 1303\u20131313 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR72","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1161\/CIRCULATIONAHA.116.023402","volume":"134","author":"F Franchi","year":"2016","unstructured":"Franchi, F.  et al. Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (optimizing antiplatelet therapy in diabetes mellitus)-4 study. Circulation 134, 780\u2013792 (2016).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR73","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12265-013-9535-3","volume":"7","author":"F Rollini","year":"2014","unstructured":"Rollini, F.  et al. Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. J. Cardiovasc. Transl Res. 7, 53\u201363 (2014).","journal-title":"J. Cardiovasc. Transl Res."},{"key":"BFnrcardio201712_CR74","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","volume":"9","author":"PC Armstrong","year":"2011","unstructured":"Armstrong, P. C.  et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J. Thromb. Haemost. 9, 552\u2013561 (2011).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrcardio201712_CR75","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1603060","volume":"375","author":"SC Johnston","year":"2016","unstructured":"Johnston, S. C.  et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N. Engl. J. Med. 375, 35\u201343 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR76","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.4244\/EIJY15M11_07","volume":"12","author":"P Vranckx","year":"2015","unstructured":"Vranckx, P.  et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention 12, 1239\u20131245 (2015).","journal-title":"EuroIntervention"},{"key":"BFnrcardio201712_CR77","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01830543 (2016)."},{"key":"BFnrcardio201712_CR78","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/clc.22572","volume":"39","author":"CP Cannon","year":"2016","unstructured":"Cannon, C. P.  et al. Design and rationale of the RE-DUAL PCI trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin. Cardiol. 39, 555\u2013564 (2016).","journal-title":"Clin. Cardiol."},{"key":"BFnrcardio201712_CR79","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01813435 (2016)."},{"key":"BFnrcardio201712_CR80","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01813435 (2016)."},{"key":"BFnrcardio201712_CR81","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02270242 (2015)."},{"key":"BFnrcardio201712_CR82","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJM198806303182603","volume":"318","author":"L Schwartz","year":"1988","unstructured":"Schwartz, L.  et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 318, 1714\u20131719 (1988).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR83","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJM199101033240103","volume":"324","author":"PW Serruys","year":"1991","unstructured":"Serruys, P. W.  et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N. Engl. J. Med. 324, 13\u201317 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR84","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1161\/01.CIR.91.6.1676","volume":"91","author":"A Colombo","year":"1995","unstructured":"Colombo, A.  et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 91, 1676\u20131688 (1995).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR85","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"ME Bertrand","year":"2000","unstructured":"Bertrand, M. E., Rupprecht, H. J., Urban, P. & Gershlick, A. H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102, 624\u2013629 (2000).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR86","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/01.CIR.103.2.192","volume":"103","author":"JE Sousa","year":"2001","unstructured":"Sousa, J. E.  et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103, 192\u2013195 (2001).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR87","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","volume":"108","author":"P Fontana","year":"2003","unstructured":"Fontana, P.  et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108, 989\u2013995 (2003).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR88","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","volume":"362","author":"SJ Park","year":"2010","unstructured":"Park, S. J.  et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N. Engl. J. Med. 362, 1374\u20131382 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio201712_CR89","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1093\/eurheartj\/ehs318","volume":"33","author":"S Cassese","year":"2012","unstructured":"Cassese, S., Byrne, R. A., Tada, T., King, L. A. & Kastrati, A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur. Heart J. 33, 3078\u20133087 (2012).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201712_CR90","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","volume":"129","author":"CW Lee","year":"2014","unstructured":"Lee, C. W.  et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation 129, 304\u2013312 (2014).","journal-title":"Circulation"},{"key":"BFnrcardio201712_CR91","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","volume":"384","author":"JP Collet","year":"2014","unstructured":"Collet, J. P.  et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC Interruption): a randomised trial. Lancet 384, 1577\u20131585 (2014).","journal-title":"Lancet"},{"key":"BFnrcardio201712_CR92","first-page":"365","volume":"37","author":"G Helft","year":"2016","unstructured":"Helft, G.  et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur. Heart J. 37, 365\u2013374 (2016).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201712_CR93","doi-asserted-by":"publisher","first-page":"e003145","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","volume":"9","author":"Y Han","year":"2016","unstructured":"Han, Y.  et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial. Circ. Cardiovasc. Interv. 9, e003145 (2016).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"BFnrcardio201712_CR94","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","volume":"64","author":"A Colombo","year":"2014","unstructured":"Colombo, A.  et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J. Am. Coll. Cardiol. 64, 2086\u20132097 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201712_CR95","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","volume":"9","author":"SJ Hong","year":"2016","unstructured":"Hong, S. J.  et al. 6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JACC Cardiovasc. Interv. 9, 1438\u20131446 (2016).","journal-title":"JACC Cardiovasc. Interv."},{"key":"BFnrcardio201712_CR96","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","volume":"60","author":"BK Kim","year":"2012","unstructured":"Kim, B. K.  et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (real safety and efficacy of 3-month dual antiplatelet therapy following Endeavor zotarolimus-eluting stent implantation). J. Am. Coll. Cardiol. 60, 1340\u20131348 (2012).","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2017.12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2017.12","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2017.12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T19:12:09Z","timestamp":1650136329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2017.12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFnrcardio201712"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2017.12","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]},"assertion":[{"value":"9 February 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.O. and P.W.S. are members of the Advisory Board for Abbott Vascular. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}